Skip to Content

Baricitinib Side Effects

Medically reviewed by Last updated on Aug 5, 2019.

For the Consumer

Applies to baricitinib: oral tablets


    Serious Infections
  • Serious, sometimes fatal infections including tuberculosis (pulmonary or extrapulmonary disease), bacterial and viral infections, invasive fungal infections (may be disseminated), and other opportunistic infections reported.1 (See Infectious Complications under Cautions.)

  • Carefully consider risks and benefits prior to initiating baricitinib therapy in patients with chronic or recurring infections.1

  • Evaluate patients for latent tuberculosis infection prior to and periodically during treatment; if indicated, initiate appropriate antimycobacterial regimen prior to initiating baricitinib therapy.1

  • Closely monitor patients for infection, including active tuberculosis in those with a negative test for latent tuberculosis, during and after treatment.1 If serious infection develops, interrupt baricitinib therapy until infection is controlled.1

  • Lymphoma and other malignancies reported.1 (See Malignancies and Lymphoproliferative Disorders under Cautions.)

  • Serious, sometimes fatal thromboembolic events, including DVT, PE, and arterial thrombosis, reported.1 Promptly evaluate patients with symptoms of thrombosis.1 (See Thromboembolic Events under Cautions.)

Side effects include:

Upper respiratory tract infection, nausea, herpes simplex, herpes zoster.

For Healthcare Professionals

Applies to baricitinib: oral tablet


Common (1% to 10%): Thrombocytosis, anemia

Uncommon (0.1% to 1%): Neutropenia

Frequency not reported: Lymphocytosis (occurs at higher rates in the elderly)[Ref]


Common (1% to 10%): Herpes zoster, herpes simplex (e.g., eczema herpeticum, herpes simplex, ophthalmic herpes simplex, oral herpes), influenza[Ref]


Common (1% to 10%): Arthralgia, rheumatoid arthritis, back pain, muscle spasm, myalgia[Ref]


Common (1% to 10%): Blurred vision

Uncommon (0.1% to 1%): Cataract[Ref]


Very common (10% or more): Hypercholesterolemia (34%)

Uncommon (0.1% to 1%): Hypertriglyceridemia, weight gain, creatine phosphokinase increased to greater than 5 times the upper limit of normal (ULN)[Ref]


Uncommon (0.1% to 1%): Insomnia, depression[Ref]


Common (1% to 10%): Urinary tract infection, benign prostatic hyperplasia

Uncommon (0.1% to 1%): Cystitis, erectile dysfunction, vulvovaginal candidiasis[Ref]


Common (1% to 10%): ALT increased greater than or equal to 3 times the upper limit of normal (ULN)

Uncommon (0.1% to 1%): AST increased greater than or equal to 3 times the upper limit of normal (ULN), abnormal hepatic function[Ref]


Very common (10% or more): Upper respiratory tract infections (e.g., sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, tonsillitis, tracheitis) (15%)

Common (1% to 10%): Bronchitis, sinusitis, rhinitis, cough

Uncommon (0.1% to 1%): Tonsillitis[Ref]


Common (1% to 10%): Fatigue, pyrexia, peripheral edema[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness[Ref]


Common (1% to 10%): Hypertension, coronary artery disease[Ref]


Uncommon (0.1% to 1%): Acne, alopecia, rash[Ref]


Common (1% to 10%): Nausea, gastroenteritis, dyspepsia, upper abdominal pain, constipation, vomiting, oropharyngeal pain, stomatitis, abdominal discomfort, gastroesophageal reflux disease[Ref]


1. "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company, Indianapolis, IN.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.